A new study has uncovered how liver cancer cells exploit oxygen-deprived environments to strengthen their defenses and evade treatment. The research, led by Hu, Li, and Chen, reveals that hypoxia—a common feature of aggressive hepatocellular carcinoma (HCC)—boosts the expression of the deubiquitinating enzyme USP13. This molecular shift stabilizes critical metabolic processes, protects tumor cells from ferroptosis, and helps them escape immune detection. The findings, published in Cell Death Discovery, suggest promising new therapeutic targets for one of the world’s deadliest cancers.
Hepatocellular carcinoma remains difficult to treat due to its high resistance to conventional therapies. Hypoxic conditions within these tumors activate survival programs that reshape protein stability and cellular metabolism. The researchers identified USP13 as a central player in this adaptive response, enabling cancer cells to maintain viability under severe stress.
A key discovery is USP13’s ability to stabilize ATP citrate lyase (ACLY), an enzyme essential for producing acetyl-CoA, a precursor for lipid synthesis and energy production. Under normal conditions, ACLY is degraded through the ubiquitin-proteasome system. Hypoxia-induced USP13 blocks this degradation, ensuring steady lipid metabolism and reinforcing the cells’ structural and energetic needs.
This stabilization also strengthens resistance to ferroptosis—an iron-dependent form of programmed cell death triggered by lipid peroxidation. By preserving ACLY and maintaining lipid homeostasis, USP13 prevents the accumulation of oxidized lipids that would otherwise kill cancer cells. As a result, HCC cells gain a crucial survival advantage in harsh tumor environments.
The study further highlights how USP13-mediated ferroptosis resistance enables tumors to evade the immune system. ACLY stabilization appears to contribute to a microenvironment that limits immune infiltration and reduces tumor visibility to immune cells. This dual protection—against cell death and immune attack—positions USP13 as a compelling therapeutic target.
To map this mechanism, the team used hypoxia-mimicking systems in cell cultures, proteomic profiling, and co-immunoprecipitation techniques. They observed strong USP13 upregulation and confirmed its direct interaction with ACLY. Mouse tumor models supported the laboratory findings: blocking USP13 reduced tumor growth and increased markers of ferroptosis.
These insights underscore the broader significance of metabolic regulation in cancer progression. The USP13–ACLY axis exemplifies how tumor cells integrate metabolic and protein-stability pathways to fuel growth and resist treatment. Because hypoxia and ferroptosis resistance are common across solid tumors, this mechanism may hold relevance beyond liver cancer.
The study also points toward new therapeutic strategies. Early tests of small-molecule USP13 inhibitors increased ACLY degradation, reduced cancer cell survival, and reactivated ferroptosis in hypoxic conditions. Such inhibitors could potentially complement immunotherapies or ferroptosis-inducing treatments, helping overcome resistance in hypoxic tumors.
By revealing how hypoxia links oxygen sensing, ubiquitination, and metabolic reprogramming, the study adds important clarity to the biology of liver cancer survival. It suggests that targeting USP13 could selectively weaken tumor cells while sparing healthier tissues, offering a path toward more precise and less toxic therapies.
Hu and colleagues’ work provides a foundation for future research on metabolic vulnerabilities in cancer. As scientists explore USP13-targeted treatments, this pathway may reshape therapeutic strategies for HCC and other hypoxia-driven malignancies.
Related topic：
